MJ Tisdale was originator of the Aston’s brain cancer drug temozolomide, which is marketed and generates in excess of 800 million turnover. MJT, a professor of cancer biochemistry, is a world leading scientist in cancer cachexia. EL in collaboration with MJT originated a series of patents and research publications in the area of cancer therapeutics. MJ Tisdale was involved with the Boehringer AG in the development of COX-2 inhibitors with a main focus later on the action of eicosapentaenoic acid (EPA) in preventing muscle catabolism in cancer cachexia. EPA was evaluated clinically for the treatment of pancreatic cancers. From cancer cachexia he turned his attention to nutrition, applications in treating type II diabetes and recently CCK antagonists based chemotherapeutics.